Skip to content

A study to assess the effects and safety of Sofinox cream (Sodium Fusidate IP equivalent to Fusidic Acid IP 2.0% w/w) and Adapalene 0.1% w/w cream in volunteers with mild to moderate acne for 12 weeks

A single arm, open label controlled 12 weeks assessment study of the efficacy and safety of topical SOFINOX cream (Sodium Fusidate IP equivalent to Fusidic Acid IP 2.0 % w/w) and Adapalene 0.1% w/w cream in volunteers with mild to moderate acne vulgaris

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/09/003989
Enrollment
72
Registered
2013-09-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Mild to moderate acne vulgaris

Interventions

Intervention1: Sofinox cream and Adapalene cream: Sofinox Cream (Sodium Fusidate IP equivalent to Fusidic Acid 2.0% w/w) cream one finger tip unit(1FTU or 0.5 gm) to be applied twice daily (morning &

Sponsors

Apex Laboratories Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Skin phototype III-V (Fitzpatrick) - Acne prone subjects showing the presence of mild to moderate facial acne vulgaris (Grade 2-7 on Leeds Acne Grading scale), presenting at least 15 inflammatory lesions and at least 25 non-inflammatory lesions on the face - Female participants with child bearing potential must have a negative urine pregnancy test at screening visit and willing to use acceptable contraceptive measures during the study.

Exclusion criteria

Exclusion criteria: - Patients with any nodulo-cystic lesions at baseline - Secondary acne and severe acne (acne fulminans, acne conglobata) - Patients with acne excoriata or having psychological disturbances Known hypersensitivity to the study drug or constituents - Any topical or systemic treatment that could interfere with the study treatments/assessments (antibiotics, corticosteroids, retinoids, antiinflammatory drugsâ?¦) within the last 4 weeks prior to participation in the study, and during the study - Any surgical treatment on the test areas - Use of hormonal contraceptives solely for the treatment of acne - Use of prohibited medications prior to the start and unwillingness to refrain from the use during the study

Design outcomes

Primary

MeasureTime frame
- Counting of cutaneous inflammatory acne lesions - Average inflammatory lesion sizeTimepoint: - Counting of cutaneous inflammatory acne lesions on day 1, 15, 29, 43, 57, 71, 85, 106 - Average inflammatory lesion size on day 1, 15, 29, 43, 57, 71, 85, 106

Secondary

MeasureTime frame
- Self-evaluation questionnaire by the subjects - Investigators assessment of improvement in acne on the basis of Leeds acne grading scale (Photographic scale) - Recurrence of target inflammatory acne lesions post subsidence - Skin conductivity with Corneometer®Timepoint: - Self-evaluation questionnaire by the subjects at D1, D43 and D85 - Investigators assessment of improvement in acne on the basis of Leeds acne grading scale (Photographic scale) on days 1, 15, 29, 43 57, 71 and 85 - Recurrence of target inflammatory acne lesions post subsidence on days 29, 43 57, 71 and 85 - Skin conductivity with Corneometer® on days 1, 15, 29, 43 57, 71 and 85

Countries

India

Contacts

Public ContactDr Aalok Makker

CIDP Biotech India Pvt. Ltd

rnangia@cidp-cro.com01140793385

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026